

Patient Name
Patient Number
DOB
Consultant

**Kent & Medway
SACT proforma**

Date measured

Protocol Number
SUPP-001

Authorising Consultant
C Abson
CSA

**Zoledronic
Acid**

For patients with advanced malignancies involving the bone (excluding prostate cancer unless used as part of a pain management programme)
**Cycle No.....days
To be given every.....days
(Either 21 or 28 days)**

Est. CrCl (ml/min)

Pharmacist:

Corrected calcium

C Blanco /C Waters Jan 14
Review by Jan 16 *Chubb*
Version 2 *Blawes*

Cr (mmol/ml)

Allergies:

Phosphate

Magnesium

- C + G should be used to estimate CrCl prior to start of treatment and if creatinine rises during treatment
- Monitor serum creatinine at each cycle. If renal function deteriorates d/w consultant
- If CrCl 30-60 ml/min dose should be reduced, see SPC
- Contra-indicated in patients with CrCl <30 ml/min.
- Monitor corrected calcium, phosphate and magnesium at each cycle
- Adecal to be dispensed every other cycle (cycles 1, 3, 5 etc)
- In multiple myeloma patients, the risk of renal dysfunction may be increased when used in combination with thalidomide
- Osteonecrosis of the jaw
- A dental examination with appropriate preventative dentistry should be considered prior to treatment
- While on treatment avoid dental procedures if possible

Disp/Admin Record

Day	Drug	Dose	Route	Infusion Duration	Administration Details	Batch No	Disp	Check	Nurses Signature	Start Time	Stop Time
1	ZOLEDRONIC ACID	4 mg	iv	15 mins	in 100ml Sodium Chloride 0.9%						
TTOs	Drug	Dose	Route	Directions		Quantity			Disp	Check	
	Calcium 600mg + colecalciferol 10 micrograms tablets (Adecal D3)	1 tablet	po	Once daily, chewed or sucked before swallowing		Dispense 56 tablets every other cycle					

Prescriber's signature:

Pharmacist's Clinical Screen:

Date:

Date:

Disclaimer: This document is for use only within Kent and Medway. No responsibility will be accepted for the accuracy of this information when used elsewhere.